605 related articles for article (PubMed ID: 28460819)
1. Design, synthesis, biological evaluation and molecular docking studies of novel 3-aryl-4-anilino-2H-chromen-2-one derivatives targeting ERα as anti-breast cancer agents.
Luo G; Chen M; Lyu W; Zhao R; Xu Q; You Q; Xiang H
Bioorg Med Chem Lett; 2017 Jun; 27(12):2668-2673. PubMed ID: 28460819
[TBL] [Abstract][Full Text] [Related]
2. Novel SERMs based on 3-aryl-4-aryloxy-2H-chromen-2-one skeleton - A possible way to dual ERα/VEGFR-2 ligands for treatment of breast cancer.
Luo G; Li X; Zhang G; Wu C; Tang Z; Liu L; You Q; Xiang H
Eur J Med Chem; 2017 Nov; 140():252-273. PubMed ID: 28942113
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of 3-aryl-quinolin derivatives as anti-breast cancer agents targeting ERα and VEGFR-2.
Li X; Wu C; Lin X; Cai X; Liu L; Luo G; You Q; Xiang H
Eur J Med Chem; 2019 Jan; 161():445-455. PubMed ID: 30384047
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
5. Synthesis, molecular docking and inhibition studies of novel 3-N-aryl substituted-2-heteroarylchromones targeting microtubule affinity regulating kinase 4 inhibitors.
Parveen I; Khan P; Ali S; Hassan MI; Ahmed N
Eur J Med Chem; 2018 Nov; 159():166-177. PubMed ID: 30290280
[TBL] [Abstract][Full Text] [Related]
6. Development of the β-lactam type molecular scaffold for selective estrogen receptor α modulator action: synthesis and cytotoxic effects in MCF-7 breast cancer cells.
Carr M; Knox AJ; Lloyd DG; Zisterer DM; Meegan MJ
J Enzyme Inhib Med Chem; 2016; 31(sup3):117-130. PubMed ID: 27476825
[TBL] [Abstract][Full Text] [Related]
7. Design, synthesis and evaluation of Ospemifene analogs as anti-breast cancer agents.
Kaur G; Mahajan MP; Pandey MK; Singh P; Ramisetti SR; Sharma AK
Eur J Med Chem; 2014 Oct; 86():211-8. PubMed ID: 25164760
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, Biological Investigation and Docking Study of Novel Chromen Derivatives as Anti-Cancer Agents.
Dube PN; Sakle NS; Dhawale SA; More SA; Mokale SN
Anticancer Agents Med Chem; 2019; 19(9):1150-1160. PubMed ID: 30848213
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel 2H-chromene-3-carbonyl derivatives as selective estrogen receptor degraders (SERDs): Design, synthesis and biological evaluation.
Lu X; Teng Y; Lin X; Xiao M; Liu C; Chi X; Zhang Y; Luo G; Xiang H
Bioorg Chem; 2021 Apr; 109():104714. PubMed ID: 33618254
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, in silico and biological evaluation of new indole based oxadiazole derivatives targeting estrogen receptor alpha.
Kaur K; Verma H; Gangwar P; Jangid K; Dhiman M; Kumar V; Jaitak V
Bioorg Chem; 2024 Jun; 147():107341. PubMed ID: 38593531
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis and evaluation of 6-aryl-indenoisoquinolone derivatives dual targeting ERα and VEGFR-2 as anti-breast cancer agents.
Tang Z; Wu C; Wang T; Lao K; Wang Y; Liu L; Muyaba M; Xu P; He C; Luo G; Qian Z; Niu S; Wang L; Wang Y; Xiao H; You Q; Xiang H
Eur J Med Chem; 2016 Aug; 118():328-39. PubMed ID: 27176944
[TBL] [Abstract][Full Text] [Related]
13. Ligand-Based Drug Design: Synthesis and Biological Evaluation of Substituted Benzoin Derivatives as Potential Antitumor Agents.
Sabbah DA; Ibrahim AH; Talib WH; Alqaisi KM; Sweidan K; Bardaweel SK; Sheikha GA; Zhong HA; Al-Shalabi E; Khalaf RA; Mubarak MS
Med Chem; 2019; 15(4):417-429. PubMed ID: 30207238
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and SAR studies of bis-chromenone derivatives for anti-proliferative activity against human cancer cells.
Venkateswararao E; Sharma VK; Manickam M; Yun J; Jung SH
Bioorg Med Chem Lett; 2014 Nov; 24(22):5256-9. PubMed ID: 25442319
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis, and anti-breast cancer evaluation of new triarylethylene analogs bearing short alkyl- and polar amino-/amido-ethyl chains.
Kaur G; Mahajan MP; Pandey MK; Singh P; Ramisetti SR; Sharma AK
Bioorg Med Chem Lett; 2016 Apr; 26(8):1963-9. PubMed ID: 26972118
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationships of 2, 4-disubstituted pyrimidines as dual ERα/VEGFR-2 ligands with anti-breast cancer activity.
Luo G; Tang Z; Lao K; Li X; You Q; Xiang H
Eur J Med Chem; 2018 Apr; 150():783-795. PubMed ID: 29587221
[TBL] [Abstract][Full Text] [Related]
17. Novel 3-(2-(3-methyl-5-substituted-phenyl-4,5-dihydropyrazol-1-yl)-2-oxoethoxy)-2-substituted-phenyl-4H-chromen-4-one: synthesis and anticancer activity.
Liu XH; Li J; Wu FR; Song BA; Bhadury PS; Shi L
Med Chem; 2011 Nov; 7(6):605-10. PubMed ID: 22313300
[TBL] [Abstract][Full Text] [Related]
18. Molecular Dynamics and Biological Evaluation of 2-chloro-7-cyclopentyl- 7H-pyrrolo[2,3-d]pyrimidine Derivatives Against Breast Cancer.
Singaram K; Marimuthu D; Baskaran S; Chinaga SK; Shanmugarajan D; Vadivel T
Comb Chem High Throughput Screen; 2017; 20(8):703-712. PubMed ID: 28738766
[TBL] [Abstract][Full Text] [Related]
19. Anticancer effects of synthetic hexahydrobenzo [g]chromen-4-one derivatives on human breast cancer cell lines.
Pordeli M; Nakhjiri M; Safavi M; Ardestani SK; Foroumadi A
Breast Cancer; 2017 Mar; 24(2):299-311. PubMed ID: 27250840
[TBL] [Abstract][Full Text] [Related]
20. ER alpha selective chromone, isoxazolylchromones, induces ROS-mediated cell death without autophagy.
Kaushik S; Sanawar R; Lekshmi A; Chandrasekhar L; Nair M; Bhatnagar S; Santhoshkumar TR
Chem Biol Drug Des; 2019 Jul; 94(1):1352-1367. PubMed ID: 31066219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]